You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsoflurophate
Accession NumberDB00677  (APRD00763)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionAn irreversible cholinesterase inhibitor with actions similar to those of echothiophate. It is a powerful miotic used mainly in the treatment of glaucoma. Its vapor is highly toxic and it is recommended that only solutions in arachis oil be used therapeutically. (From Martindale, The Extra Pharmacopoeia, 29th ed, p1330)
Structure
Thumb
Synonyms
DFP
Diisopropoxyphosphoryl Fluoride
Diisopropyl fluorophosphate
Diisopropyl Fluorophosphonate
Diisopropyl Phosphofluoridate
Diisopropyl Phosphorofluoridate
Diisopropylfluorophosphate
Diisopropylfluorophosphoric acid ester
Diisopropylphosphofluoridate
Diisopropylphosphorofluoridate
Fluorodiisopropyl Phosphate
Fluorostigmine
Isofluorphate
Isoflurophate
Isoflurophosphate
Isopropyl fluophosphate
Isopropyl Phosphorofluoridate
Neoglaucit
O,O'-diisopropyl phosphoryl fluoride
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DiflupylNot Available
FloroprylMerck
FluoprylMerck
Brand mixturesNot Available
SaltsNot Available
Categories
UNII12UHW9R67N
CAS number55-91-4
WeightAverage: 184.1457
Monoisotopic: 184.066459031
Chemical FormulaC6H14FO3P
InChI KeyInChIKey=MUCZHBLJLSDCSD-UHFFFAOYSA-N
InChI
InChI=1S/C6H14FO3P/c1-5(2)9-11(7,8)10-6(3)4/h5-6H,1-4H3
IUPAC Name
bis(propan-2-yl) fluorophosphonate
SMILES
CC(C)OP(F)(=O)OC(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phosphate esters. These are organic compounds containing phosphoric acid ester functional group, with the general structure R1P(=O)(R2)OR3. R1,R2 = O,N, or halogen atom; R3 = organyl group.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphoric acids and derivatives
Sub ClassPhosphate esters
Direct ParentPhosphate esters
Alternative Parents
Substituents
  • Phosphoric acid ester
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationFor use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia.
PharmacodynamicsIsoflurophate is used as ocular drops in the treatment of chronic glaucoma. Isoflurophate is an organophosphorus compound that acts as an irreversible cholinesterase inhibitor. As such, it displays parasympathomimetic effects. Isoflurophate is used in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia. They may also be used in the diagnosis of certain eye conditions, such as accommodative esotropia. Isoflurophate damages the acetylcholinesterase enzyme and is therefore irreversible, however, pralidoxime can displace organophosphates such as isoflurophate from acetylcholinesterase, but only if administered before isoflurophate damages (alkylates) the enzyme.
Mechanism of actionThe mechanism of isoflurophate's action involves the irreversible inhibition of cholinesterase.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySigns of overdose include increased sweating, loss of bladder control, muscle weakness, nausea, vomiting, diarrhea, or stomach cramps or pain, shortness of breath, tightness in chest, or wheezing, slow or irregular heartbeat, unusual tiredness or weakness, watering of mouth.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9803
Caco-2 permeable-0.5386
P-glycoprotein substrateNon-substrate0.8483
P-glycoprotein inhibitor INon-inhibitor0.7683
P-glycoprotein inhibitor IINon-inhibitor0.9518
Renal organic cation transporterNon-inhibitor0.9541
CYP450 2C9 substrateNon-substrate0.8393
CYP450 2D6 substrateNon-substrate0.8447
CYP450 3A4 substrateNon-substrate0.5232
CYP450 1A2 substrateNon-inhibitor0.8174
CYP450 2C9 inhibitorNon-inhibitor0.8396
CYP450 2D6 inhibitorNon-inhibitor0.9132
CYP450 2C19 inhibitorNon-inhibitor0.7248
CYP450 3A4 inhibitorNon-inhibitor0.8834
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9185
Ames testNon AMES toxic0.8082
CarcinogenicityCarcinogens 0.8124
BiodegradationNot ready biodegradable0.8938
Rat acute toxicity4.5346 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9572
hERG inhibition (predictor II)Non-inhibitor0.8508
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
boiling point62 @ 9mm, 46 @ 5mmU.S. Patent 2,409,039.
water solubility1.54E+004 mg/L (at 25 °C)MERCK INDEX (1996)
logP1.17CZERWINSKI,SE ET AL. (1998)
Predicted Properties
PropertyValueSource
Water Solubility6.78 mg/mLALOGPS
logP1.1ALOGPS
logP1.76ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)-9.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity40.89 m3·mol-1ChemAxon
Polarizability16.75 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 2,409,039.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57.7 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Isoflurophate.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Isoflurophate.
AcebutololIsoflurophate may increase the bradycardic activities of Acebutolol.
AcetylcholineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Acetylcholine.
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Isoflurophate.
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Isoflurophate.
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Isoflurophate.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Isoflurophate.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Isoflurophate.
AlprenololIsoflurophate may increase the bradycardic activities of Alprenolol.
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Isoflurophate.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Isoflurophate.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Isoflurophate.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Isoflurophate.
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Isoflurophate.
ArecolineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Arecoline.
ArotinololIsoflurophate may increase the bradycardic activities of Arotinolol.
AtenololIsoflurophate may increase the bradycardic activities of Atenolol.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Isoflurophate.
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Isoflurophate.
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Isoflurophate.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Isoflurophate.
BefunololIsoflurophate may increase the bradycardic activities of Befunolol.
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Isoflurophate.
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Isoflurophate.
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Isoflurophate.
BetaxololIsoflurophate may increase the bradycardic activities of Betaxolol.
BethanecholThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Bethanechol.
BevantololIsoflurophate may increase the bradycardic activities of Bevantolol.
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Isoflurophate.
BisoprololIsoflurophate may increase the bradycardic activities of Bisoprolol.
BoceprevirThe serum concentration of Isoflurophate can be decreased when it is combined with Boceprevir.
BopindololIsoflurophate may increase the bradycardic activities of Bopindolol.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Isoflurophate.
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Isoflurophate.
BufuralolIsoflurophate may increase the bradycardic activities of Bufuralol.
BupranololIsoflurophate may increase the bradycardic activities of Bupranolol.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Isoflurophate.
CarbacholThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Carbachol.
CarbamazepineThe metabolism of Isoflurophate can be increased when combined with Carbamazepine.
CarteololIsoflurophate may increase the bradycardic activities of Carteolol.
CarvedilolIsoflurophate may increase the bradycardic activities of Carvedilol.
CeliprololIsoflurophate may increase the bradycardic activities of Celiprolol.
CevimelineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cevimeline.
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Isoflurophate.
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Isoflurophate.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Isoflurophate.
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Isoflurophate.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Isoflurophate.
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Isoflurophate.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Isoflurophate.
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Isoflurophate.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Isoflurophate.
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Isoflurophate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Isoflurophate.
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Isoflurophate.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Isoflurophate.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Isoflurophate.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Isoflurophate.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Isoflurophate.
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Isoflurophate.
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Isoflurophate.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Isoflurophate.
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Isoflurophate.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Isoflurophate.
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Isoflurophate.
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Isoflurophate.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Isoflurophate.
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Isoflurophate.
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Isoflurophate.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Isoflurophate.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Isoflurophate.
DipyridamoleThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Dipyridamole.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Isoflurophate.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Isoflurophate.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Isoflurophate.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Isoflurophate.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Isoflurophate is combined with EPIBATIDINE.
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Isoflurophate.
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Isoflurophate.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Isoflurophate.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Isoflurophate.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Isoflurophate.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Isoflurophate.
EsmololIsoflurophate may increase the bradycardic activities of Esmolol.
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Isoflurophate.
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Isoflurophate.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Isoflurophate.
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Isoflurophate.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Isoflurophate.
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Isoflurophate.
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Isoflurophate.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Isoflurophate.
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Isoflurophate.
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Isoflurophate.
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Isoflurophate.
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Isoflurophate.
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Isoflurophate.
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Isoflurophate.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Isoflurophate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Isoflurophate.
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Isoflurophate.
GarlicThe serum concentration of Isoflurophate can be decreased when it is combined with Garlic.
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Isoflurophate.
GTS-21The risk or severity of adverse effects can be increased when Isoflurophate is combined with GTS-21.
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Isoflurophate.
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Isoflurophate.
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Isoflurophate.
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Isoflurophate.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Isoflurophate.
IndenololIsoflurophate may increase the bradycardic activities of Indenolol.
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Isoflurophate.
LabetalolIsoflurophate may increase the bradycardic activities of Labetalol.
LobelineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Lobeline.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Isoflurophate.
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Isoflurophate.
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Isoflurophate.
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Isoflurophate.
MethacholineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Methacholine.
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Isoflurophate.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Isoflurophate.
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Isoflurophate.
MetoprololIsoflurophate may increase the bradycardic activities of Metoprolol.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Isoflurophate.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Isoflurophate.
MivacuriumIsoflurophate may decrease the neuromuscular blocking activities of Mivacurium.
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Isoflurophate.
N-butylscopolammonium bromideThe therapeutic efficacy of N-butylscopolammonium bromide can be decreased when used in combination with Isoflurophate.
NadololIsoflurophate may increase the bradycardic activities of Nadolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Isoflurophate.
NicotineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Nicotine bitartrate.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Isoflurophate.
NVA237The therapeutic efficacy of NVA237 can be decreased when used in combination with Isoflurophate.
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Isoflurophate.
OxprenololIsoflurophate may increase the bradycardic activities of Oxprenolol.
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Isoflurophate.
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Isoflurophate.
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Isoflurophate.
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Isoflurophate.
PenbutololIsoflurophate may increase the bradycardic activities of Penbutolol.
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Isoflurophate.
PethidineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Pethidine.
PilocarpineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Pilocarpine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Isoflurophate.
PindololIsoflurophate may increase the bradycardic activities of Pindolol.
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Isoflurophate.
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Isoflurophate.
PractololIsoflurophate may increase the bradycardic activities of Practolol.
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Isoflurophate.
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Isoflurophate.
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Isoflurophate.
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Isoflurophate.
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Isoflurophate.
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Isoflurophate.
PropranololIsoflurophate may increase the bradycardic activities of Propranolol.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Isoflurophate.
QuinidineThe therapeutic efficacy of Quinidine can be decreased when used in combination with Isoflurophate.
RapacuroniumIsoflurophate may decrease the neuromuscular blocking activities of Rapacuronium.
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Isoflurophate.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Isoflurophate.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Isoflurophate.
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Isoflurophate.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Isoflurophate.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Isoflurophate.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Isoflurophate.
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Isoflurophate.
SotalolIsoflurophate may increase the bradycardic activities of Sotalol.
St. John's WortThe metabolism of Isoflurophate can be increased when combined with St. John's Wort.
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Isoflurophate.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Isoflurophate.
TemsirolimusThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Temsirolimus.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Isoflurophate.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Isoflurophate.
TimololIsoflurophate may increase the bradycardic activities of Timolol.
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Isoflurophate.
TipranavirThe serum concentration of Isoflurophate can be decreased when it is combined with Tipranavir.
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Isoflurophate.
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Isoflurophate.
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Isoflurophate.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Isoflurophate.
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Isoflurophate.
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Isoflurophate.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Isoflurophate.
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Isoflurophate.
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Isoflurophate.
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Isoflurophate.
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Isoflurophate.
VareniclineThe risk or severity of adverse effects can be increased when Isoflurophate is combined with Varenicline.
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Isoflurophate.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Isoflurophate.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine hydrolase activity
Specific Function:
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name:
ACHE
Uniprot ID:
P22303
Molecular Weight:
67795.525 Da
References
  1. Malatova Z, Gottlieb M, Marsala J: Depression of acetylcholinesterase synthesis following transient cerebral ischemia in rat: pharmacohistochemical and biochemical investigation. Gen Physiol Biophys. 1999 Mar;18(1):57-71. [PubMed:10378121 ]
  2. Quistad GB, Zhang N, Sparks SE, Casida JE: Phosphoacetylcholinesterase: toxicity of phosphorus oxychloride to mammals and insects that can be attributed to selective phosphorylation of acetylcholinesterase by phosphorodichloridic acid. Chem Res Toxicol. 2000 Jul;13(7):652-7. [PubMed:10898598 ]
  3. da Costa VL Jr, Lapa AJ, Godinho RO: Short- and long-term influences of calcitonin gene-related peptide on the synthesis of acetylcholinesterase in mammalian myotubes. Br J Pharmacol. 2001 May;133(2):229-36. [PubMed:11350858 ]
  4. Pang YP, Kollmeyer TM, Hong F, Lee JC, Hammond PI, Haugabouk SP, Brimijoin S: Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502. [PubMed:12837382 ]
  5. Ashani Y, Gentry MK, Doctor BP: Differences in conformational stability between native and phosphorylated acetylcholinesterase as evidenced by a monoclonal antibody. Biochemistry. 1990 Mar 13;29(10):2456-63. [PubMed:1692236 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Kamata R, Saito S, Suzuki T, Takewaki T, Kobayashi H: Correlation of binding sites for diisopropyl phosphorofluoridate with cholinesterase and neuropathy target esterase in membrane and cytosol preparations from hen. Neurotoxicology. 2001 Apr;22(2):203-14. [PubMed:11405252 ]
  2. Acey RA, Bailey S, Healy P, Jo C, Unger TF, Hudson RA: A butyrylcholinesterase in the early development of the brine shrimp (Artemia salina) larvae: a target for phthalate ester embryotoxicity? Biochem Biophys Res Commun. 2002 Dec 13;299(4):659-62. [PubMed:12459190 ]
  3. Pittel Z, Cohen S, Fisher A, Heldman E: Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes. Brain Res. 1992 Jul 17;586(1):148-51. [PubMed:1511344 ]
  4. Miller RB, Blank CL: Determination of serum cholinesterase activity by liquid chromatography with electrochemical detection. Anal Biochem. 1991 Aug 1;196(2):377-84. [PubMed:1776688 ]
  5. Kelly SS, Ferry CB, Bamforth JP: The effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles. Br J Pharmacol. 1990 Apr;99(4):721-6. [PubMed:2361169 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Kamata R, Saito S, Suzuki T, Takewaki T, Kobayashi H: Correlation of binding sites for diisopropyl phosphorofluoridate with cholinesterase and neuropathy target esterase in membrane and cytosol preparations from hen. Neurotoxicology. 2001 Apr;22(2):203-14. [PubMed:11405252 ]
  2. Acey RA, Bailey S, Healy P, Jo C, Unger TF, Hudson RA: A butyrylcholinesterase in the early development of the brine shrimp (Artemia salina) larvae: a target for phthalate ester embryotoxicity? Biochem Biophys Res Commun. 2002 Dec 13;299(4):659-62. [PubMed:12459190 ]
  3. Pittel Z, Cohen S, Fisher A, Heldman E: Differential long-term effect of AF64A on [3H]ACh synthesis and release in rat hippocampal synaptosomes. Brain Res. 1992 Jul 17;586(1):148-51. [PubMed:1511344 ]
  4. Miller RB, Blank CL: Determination of serum cholinesterase activity by liquid chromatography with electrochemical detection. Anal Biochem. 1991 Aug 1;196(2):377-84. [PubMed:1776688 ]
  5. Kelly SS, Ferry CB, Bamforth JP: The effects of anticholinesterases on the latencies of action potentials in mouse skeletal muscles. Br J Pharmacol. 1990 Apr;99(4):721-6. [PubMed:2361169 ]
  6. Masson P, Fortier PL, Albaret C, Froment MT, Bartels CF, Lockridge O: Aging of di-isopropyl-phosphorylated human butyrylcholinesterase. Biochem J. 1997 Oct 15;327 ( Pt 2):601-7. [PubMed:9359435 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23